CAR T cell News and Research

RSS
USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

CAR T-cell therapy enters into Phase I clinical trial

CAR T-cell therapy enters into Phase I clinical trial

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

CARsgen announces completion of series A financing

CARsgen announces completion of series A financing

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Engineered immune cells show antitumor activity in two patients with advanced cancers

Engineered immune cells show antitumor activity in two patients with advanced cancers

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Cancer experts to discuss latest developments and implications of cell therapies in oncology

New immunotherapies are seldom developed for childhood cancer

New immunotherapies are seldom developed for childhood cancer